Colony-stimulating factors in stem cell transplantation: Effect on quality of life

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 2, 2001, Pages 215-228

  Godder, K T ^a   Henslee Downey, P J ^a  

^a Department of Obstetrics and Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INFECTION; MEDICAL INFORMATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0035011932     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160151134881     Document Type: Review

References (93)

1. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
2. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
3. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines
4. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation
5. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation
6. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer
7. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer
8. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation
9. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer
10. Retrospective analysis of infectious disease in patients who received Leukine versus patients not receiving a cytokine who underwent autologous bone marrow transplant (ABMT) for treatment of lymphoid cancer
11. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation
12. Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors
13. Quality of life end points in cancer clinical trials: Review and recommendations
14. Lessons learned from measuring health-related quality of life in oncology
15. Health-related quality of life in women with breast cancer undergoing autologous stem-cell transplantation
16. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma
17. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
18. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation
19. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia
20. GM-CSF after allogeneic bone marrow transplantation: Accelerated recovery of neutrophils, monocytes and lymphocytes
21. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation
22. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: A cross-sectional study of the EORTC-GIMEMA AML 8A trial
23. Physical and psychological functioning of 117 survivors of bone marrow transplantation
24. Oral complications in patients with advanced cancer
25. Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation
26. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation
27. Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (sargramostim): Results of a double-blind prospective study by the Eastern Cooperative Oncology Group
28. Employment of recombinant human granulocyte-macrophage colony stimulating factor in oesophageal candidiasis in AIDS patients
29. Use of granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to fluconazole in antifungal refractory oropharyngeal candidiasis in advanced AIDS patients
30. White cell enhancement in the treatment of severe candidosis
31. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantations: A retrospective analysis
32. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
33. Quality of life following bone marrow transplantation for breast cancer: A comparative study
34. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: Results of a randomized BNLI trial
35. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation
36. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia
37. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin
38. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
39. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trials
40. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection
41. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immunodeficiency syndrome-associated Kaposi's sarcoma
42. Filgrastim (r-metHuG-CSF): The first 10 years
43. Pathophysiology and treatment of severe chronic neutropenia
44. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis
45. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor
46. An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children
47. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors
48. Hematopoietic growth factor after autologous peripheral blood transplantation: Comparison of G-CSF and GM-CSF
49. Comparison of G-CSF and GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant
50. GM-CSF enhances the antileukemic effect of partially mismatched related donor stem cell transplant
51. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation
52. Hematopoietic growth factors for graft failure after bone marrow transplantation: A randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF
53. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: A retrospective analysis of a 10-year single institution experience
54. + cell immunomagnetic selection in breast cancer patients: Effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation
55. - cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue
56. + cell level in patients undergoing stem cell mobilization
57. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: A single center experience
58. Haploidentical BMT for acute leukemia: Single-center experience of 220 patients. Large numbers of stem cells are not required for successful engraftment in partially mismatched related donor transplant
59. Randomized comparison of G-CSF + GM-CSF vs. G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
60. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells
61. GM-CSF primed autologous bone marrow transplantation
62. Priming of bone marrow harvest with GM-CSF
63. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability
64. + subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both
65. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation
66. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo
67. Mobilization and collection of peripheral blood progenitor cells (PBPC) from normal subjects treated sequentially with GM-CSF and G-CSF
68. Peripheral blood hematopoietic progenitor cells of cytokine-stimulated healthy donors as an alternative for allogeneic transplantation
69. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: A study of 29 patients
70. Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation
71. Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies
72. Effect of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer
73. Depression and body image following mastectomy and lumpectomy
74. Quality of life assessment of patients in extremity sarcoma clinical trials
75. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma
76. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae
77. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans
78. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF
79. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils
80. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: Role of the capsule, opsonins, and culture surface, and cytokines
81. Activation of human peripheral blood mononuclear cells by interleukin-2 adn granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans
82. Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts
83. Granulocyte-macrophage colony-stimulating factor augments neutrophil killing of Torulopsis glabrata and stimulates neutrophil respiratory burst and degranulation
84. Differential mechanisms of intracellular killing of Mycobacterium avium and Listeria monocytogenes by activated human and murine macrophages. The role of nitric oxide
85. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: Killing effector mechanism depends on the generation of reactive nitrogen intermediates
86. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposimal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-intracellulare
87. Use of granulocyte-macrophage colony stimulating factor in the treatment of prolonged haematopoietic dysfunction after chemotherapy alone or chemotherapy plus bone marrow transplantation
88. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy
89. Drug formulary review process for sargramostim and filgrastim: Focus on analysis of adverse drug reactions
90. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor
91. Drug therapy: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
92. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjuvant to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia
93. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia